Omecamtiv mecarbil
Sponsors
Cytokinetics Inc., Cytokinetics
Conditions
Chronic Heart Failure With Reduced Ejection FractionHealthy VolunteerHeart FailureHeart Failure With Reduced Ejection Fraction
Phase 1
A Pharmacokinetic and Pharmacodynamic Study of Omecamtiv Mecarbil in Healthy Volunteers
CompletedNCT01380223
Start: 2005-08-31End: 2006-04-30Updated: 2015-10-14
Pharmacokinetics and Safety Study of Omecamtiv Mecarbil in Healthy Japanese Adults
CompletedNCT02601001
Start: 2015-11-13End: 2016-01-06Updated: 2021-07-27
Phase 2
Pharmacokinetic Study of Omecamtiv Mecarbil in Heart Failure Patients
WithdrawnNCT01077167
Start: 2010-07-31End: 2011-05-31Updated: 2021-07-30
Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart Failure (ATOMIC-AHF)
CompletedNCT01300013
Start: 2011-04-30End: 2013-09-30Updated: 2021-07-27
Phase 3
Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection Fraction
CompletedNCT02929329
Start: 2017-01-06End: 2020-09-14Updated: 2021-11-05
Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart Failure
CompletedNCT03759392
Start: 2019-04-09End: 2022-01-06Updated: 2023-03-07
Omecamtiv Mecarbil Post-trial Access Study
WithdrawnNCT04464525
Start: 2020-12-18End: 2026-11-27Updated: 2021-07-30
A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial to Assess Efficacy and Safety of Omecamtiv Mecarbil in Patients with Symptomatic Heart Failure with Severely Reduced Ejection Fraction
RecruitingCTIS2024-519219-32-00
Start: 2025-06-23Target: 770Updated: 2026-01-21